NeuroPace, Inc. (NASDAQ:NPCE) Insider Sells $1,074,742.48 in Stock

NeuroPace, Inc. (NASDAQ:NPCE) insider Martha Morrell sold 78,334 shares of the business’s stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $13.72, for a total transaction of $1,074,742.48. Following the completion of the sale, the insider now owns 81,993 shares of the company’s stock, valued at approximately $1,124,943.96. The trade was a 48.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Martha Morrell also recently made the following trade(s):

• On Wednesday, January 29th, Martha Morrell sold 100 shares of NeuroPace stock. The shares were sold at an average price of $15.00, for a total transaction of $1,500.00.
• On Friday, January 24th, Martha Morrell sold 3,200 shares of NeuroPace stock. The shares were sold at an average price of $15.01, for a total transaction of $48,032.00.

NeuroPace Trading Up 2.4 %

NPCE stock traded up $0.32 during midday trading on Tuesday, reaching $13.84. 213,262 shares of the company’s stock traded hands, compared to its average volume of 240,635. The company has a market capitalization of $413.12 million, a P/E ratio of -13.84 and a beta of 2.05. The company has a debt-to-equity ratio of 6.03, a current ratio of 5.59 and a quick ratio of 4.77. NeuroPace, Inc. has a fifty-two week low of $5.45 and a fifty-two week high of $17.37. The business has a 50-day moving average price of $12.53 and a two-hundred day moving average price of $9.50.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. KCK LTD. acquired a new position in NeuroPace during the fourth quarter valued at approximately $58,981,000. Geode Capital Management LLC lifted its position in shares of NeuroPace by 1.8% during the fourth quarter. Geode Capital Management LLC now owns 322,973 shares of the company’s stock worth $3,615,000 after purchasing an additional 5,781 shares in the last quarter. Northern Trust Corp lifted its position in shares of NeuroPace by 15.7% during the fourth quarter. Northern Trust Corp now owns 184,847 shares of the company’s stock worth $2,068,000 after purchasing an additional 25,035 shares in the last quarter. State Street Corp lifted its position in shares of NeuroPace by 9.1% during the third quarter. State Street Corp now owns 155,490 shares of the company’s stock worth $1,084,000 after purchasing an additional 12,912 shares in the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of NeuroPace during the fourth quarter worth $1,120,000. 78.83% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on NPCE. Wells Fargo & Company boosted their target price on shares of NeuroPace from $13.00 to $17.00 and gave the company an “overweight” rating in a report on Thursday, January 30th. JPMorgan Chase & Co. boosted their target price on shares of NeuroPace from $9.00 to $14.00 and gave the company an “overweight” rating in a report on Tuesday, December 17th. Finally, UBS Group initiated coverage on shares of NeuroPace in a report on Tuesday, January 21st. They issued a “buy” rating and a $17.00 target price for the company. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $14.80.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.